Call Is Confidential & Toll Free

Kombiglyze Xr

Kombiglyze Xr (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP -4) inhibitor class of drugs. FDA approved on July 31, 2009.

Post-administration of kombiglyze xr, GLP-1 and GIP levels rise up to 2- to 3- fold. Because it is very selective of DPP-4 inhibition, there are fewer systemic side effects. Kombiglyze Xr inhibits DPP-4 enzyme activity for a 24-hour period. It also decreased glucagon concentrations and increased glucose-dependent insulin secretion from pancreatic beta cells. The half maximal inhibitory concentration (IC50) is 0.5 nmol/L. Kombiglyze Xr did not prolong the QTc interval to a clinically significant degree.

Adverse reactions reported in ≥5% of patients treated with kombiglyze xr and more commonly than in patients treated with placebo are: upper respiratory tract infection, urinary tract infection, and headache.


Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?